Outcome | ≥20% Strength improvement in ≥1 myotome | Risk (95% CI)* | RR (95% CI)† | P value‡ | |
Group | Yes | No | |||
Lidocaine | 44 (73.3) | 16 (26.7) | 73.3 (60.7 to 83.1) | 1.16 (0.91 to 1.48) | 0.239 |
Saline | 38 (63.3) | 22 (36.7) | 63.3 (50.4 to 74.6) | ||
Total | 82 (68.3) | 38 (31.7) | 68.3 (59.4 to 76.1) | ||
Outcome | ≥20% Weakness and strength change in ≥2 myotomes | ||||
Lidocaine | 14 (23.3) | 46 (76.7) | 23.3 (14.3 to 35.8) | 0.93 (0.49 to 1.76) | 0.831 |
Saline | 15 (25.0) | 45 (75.0) | 25.0 (15.6 to 37.6) | ||
Total | 29 (24.2) | 91 (75.8) | 24.2 (17.3 to 32.7) | ||
Outcome | ≥2 on NRS (MCID) | ||||
Lidocaine | 24 (40.1) | 35 (59.3) | 40.7 (28.1 to 53.2) | 1.33 (0.81 to 2.18) | 0.249 |
Saline | 18 (30.5) | 41 (69.5) | 30.51 (18.8 to 42.3) | ||
Total | 42 (35.6) | 76 (64.4) | 35.6 (27.0 to 44.2) |
Values are frequency (%) unless specified otherwise.
*Risk (%) = (freq (yes) / freq (total))×100
†Relative risk=risk (lidocaine) / risk (saline)
‡P value from Pearson's χ2 test.
freq, frequency; MCID, minimal clinically important difference; NRS, numerical rating scale; RR, relative risk.